Successful treatment of melanoma is still challenging, because metastasis remain chemoresistant and radioresistant. Accordingly, combinational treatments involving death ligands are mandatory. In a recent study from our lab, the majority out of 18 melanoma cell lines remained resistant against treatment with the death ligand TRAIL (tumor necrosis factor related apoptosis inducing ligand). Resistance was shown to be mainly due to incomplete processing of caspase-3 into catalytically inactive p21 by binding of the anti-apoptotic protein X-linked inhibitor of apoptosis protein (XIAP). Coirradiation with sub-lethal ultraviolet (UV) B caused depletion of XIAP resulting in synergistic sensitization of all but two melanoma cell lines to TRAIL. We show here the XIAP depletion to essentially require initial caspasemediated cleavage, which promotes proteasomal degradation of XIAP. Utilizing specific caspase inhibitors and small interfering RNA-mediated knockdown, we further identified caspase-3 to be responsible for performing the initial cleavage of XIAP after UVB treatment. Additional evidence suggests an accelerated mitochondrial outer membrane permeabilization in response to co-treatment with TRAIL and UVB, which directs the release of XIAP antagonizing factors including Smac. Distraction of XIAP consequently liberates caspase-3 to autocatalytically process into active p17. Activated caspase-3 cleaves XIAP and further enhances its activation in a positive regulatory feedback loop. The molecular mechanism discovered here appears to have broader implications, because cleavage of XIAP was also shown to accompany cisplatin-induced sensitization of melanoma cells to TRAIL.
Introduction
The most intensively studied inhibitor of apoptosis protein (IAP) family member, XIAP (X-linked IAP), is a 57 kDa protein which appears to be ubiquitously expressed in adult and fetal tissues (Hunter et al., 2007) . XIAP consists of three BIR domains (baculoviral IAP repeat 1-3), a RING-finger domain conferring ubiquitin (Ub) protein ligase (E3) activity and a recently discovered evolutionarily conserved Ub-acceptor (UBA) domain (Gyrd-Hansen et al., 2008; Srinivasula and Ashwell, 2008) . XIAP was identified as the only cellular protein being able to bind caspase-3, -7 and -9 directly and to inhibit both the initiation and the execution phase of apoptosis (Deveraux et al., 1999) . Given its role in apoptosis and its frequently elevated expression in malignant cells, XIAP has been considered as a promising therapeutic target in mammalian cancer. Consequently, research efforts have lately been focused on the development of drugs targeting XIAP (IAP inhibitors), which are currently being evaluated in clinical trials (Schimmer et al., 2006) .
Pro-apoptotic second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI (Smac/DIABLO), being released from mitochondria during the onset of intrinsic apoptosis, is known to functionally inhibit XIAP by distracting the protein from caspases (Du et al., 2000; Sun et al., 2008) . Full autocatalytic processing of released caspases consequently executes the apoptotic process, while the fate of XIAP is still discussed. Smac/DIABLO-dependent and -independent mechanisms have been described to mediate ubiquitination and proteasomal degradation of XIAP thereby enhancing apoptosis (Fu et al., 2003; Yang and Du, 2004; Sohn et al., 2006; Liu et al., 2007; Galban and Duckett, 2009 ). Vice versa, there are numerous reports implying E3 activity of XIAP to cause ubiquitination and immediate proteasomal degradation of pro-apoptotic XIAP counterparts, including cytosolic Smac/DIABLO (MacFarlane et al., 2002; Morizane et al., 2005; Rehm et al., 2006) , caspase-9 (Morizane et al., 2005) , caspase-7 (Creagh et al., 2004) and caspase-3 (Suzuki et al., 2001; Chen et al., 2003) , thereby directing them to proteasomal degradation. Taken together, the cellular decision between pro-and anti-apoptotic responses underlies the regulation of caspase activity mainly provided by a multilayered cross-talk between XIAP and caspases and intracellular regulator circuits including mitochondria and proteasomes.
Malignant melanoma represents one of the most aggressive malignancies with a highly chemoresistant and radioresistant metastatic stage (Flaherty, 2006) , offering a poor prognosis for affected patients (Lasithiotakis et al., 2006) . Therefore, therapeutic strategies combining chemotherapeutic drugs and tumor selective death ligands are under investigation to improve cancer treatment (Ganten et al., 2006; Zhang et al., 2006; Koschny et al., 2007) . An effective offence to malignant melanoma with the tumor selective ligand TRAIL (tumor necrosis-related apoptosis inducing ligand; Walczak et al., 1999) is curtailed by the fact that many melanoma cell lines are a priori resistant against TRAIL-induced apoptosis (Zeise et al., 2004) . On investigating 18 melanoma cell lines, we could recently show that TRAIL susceptibility was completely independent of the tumor progression stage, while only the minority of cell lines responded to TRAIL at all (Thayaparasingham et al., 2009) . Co-exposure to a nonapoptotic UV (ultraviolet) B dose was shown to highly synergistically sensitize all melanoma cell lines to TRAIL-induced apoptosis, providing an excellent tool to study the mechanism underlying TRAIL resistance. TRAIL insensitivity was based on incomplete caspase-3 processing into the catalytic inactive p21 fragment only, while UVB-induced sensitization coincided with XIAP depletion, completion of caspase-3 activation yielding the catalytically active p17, and consequently apoptosis induction (Thayaparasingham et al., 2009) . Investigating TRAIL resistance of melanoma cells and their synergistic sensitization by sub-lethal UVB, we revealed a novel mechanism involving caspase-3-induced cleavage of XIAP as a prerequisite for its proteasomal degradation. Our data elucidate the nodal point causing TRAIL resistance in melanoma and may consequently help to open new doors for tumorselective killing.
Results
Caspase-mediated proteolytic cleavage of XIAP promotes its proteasomal degradation and sensitization of melanoma cells to TRAIL Resistance of melanoma cells to TRAIL-induced apoptosis has been shown to be independent of the tumor progression stage but to correlate with XIAPdependent inhibition of full caspase-3 processing (Thayaparasingham et al., 2009) . Treating three melanoma cell lines representing the radial growth phase (RGP), the vertical growth phase (VGP) and the metastatic stage (MM) with 100 ng/ml TRAIL did not yield appreciable amounts of apoptosis, staying below 10%. Co-irradiating cells with a sub-lethal UVB dose (200 J/m 2 ), however, resulted in a highly synergistic apoptotic response after 16 h (Figure 1a) . Strikingly, primary melanocytes remained fully resistant (Figure 1a) , demonstrating the impact of this treatment as a new potent therapeutic protocol for melanoma. According to previous findings, caspase-3 processing froze at the level of the catalytically inactive p21 fragment 6 h after TRAIL treatment. Irradiation with sub-lethal UVB alone did not cause any caspase-3 cleavage, whereas the co-treatment resulted in loss of XIAP and full caspase-3 processing into the catalytically active p17 fragment (Figure 1b) . To inquire whether XIAP depletion during apoptosis induction is dependent on proteasomal degradation, cells were treated with the proteasome inhibitor MG132 before TRAIL þ UVB stimulation. Strikingly, proteasomal inhibition regained only a truncated 29 kDa form of XIAP, whereas no accumulation of the full-length protein could be detected. This suggests proteolytic processing of XIAP to be responsible for generation of the 29 kDa XIAP fragment, which is subsequently committed to proteasomal degradation (Figure 1c) . This assumption was supported by the observation that apoptosis induction-as documented by poly (ADP-ribose) polymerase cleavage-clearly coincided with decrease in wt-XIAP, but with accumulation of the c-terminal cleavage product D1-241-XIAP in cells ectopically expressing both variants and treated with the proteasome inhibitor MG132 (Figure 1d ). Of note, in primary melanocytes, XIAP depletion did not occur when using identical TRAIL þ UVB doses and even remained absent when treating these primary cells with a high dose of 500 ng/ ml TRAIL and 400 J/m 2 UVB (Figure 1c ), proposing a tumorselective mechanism.
Based on biochemical cell-free analyses, caspases have been previously shown to be capable of cleaving XIAP and the data provided identified a specific caspasecleavage motive in XIAP (Deveraux et al., 1999) . Accordingly, the contribution of caspases in XIAP processing was exemplarily investigated using the melanoma cell line WM-115 (vertical growth phase). Application of pan caspase inhibitors (Q-Val-Asp(nonomethylated)-OPhMe)inhibitor (QVD); z-Val-Ala-Asp (OMe)-FMK (zVAD)) completely prevented depletion of XIAP upon TRAIL þ UVB treatment and also circumvented stabilization of truncated XIAP upon concomitant proteasome inhibition (Figure 2a ). Using specific inhibitors for caspase-6 (z-Val-Glu-Ile-Asp(OMe)-FMK, (zVEID)), -8 (z-Ile-Glu-Thr-Asp(OMe)-FMK (zIETD)), -3 (z-Asp-Glu-Val-Asp(OMe)-FMK, (zDEVD)) and -9 (z-Leu-Glu-His-Asp(OMe)-FMK, (zLEHD)), analysis of XIAP depletion revealed that any of the tested caspases could potentially be involved in XIAP processing, with caspase-9 being less effective (Figure 2a) . Correspondingly, caspase-9 inhibition had only a minor effect on apoptosis inhibition compared with the other caspases ( Figure 2b ). Following this line, ectopic expression of an XIAP variant in which the caspase cleavage motive was mutated (myc-XIAP-D242E) was shown to be prevented from depletion by TRAIL þ UVB stimulation compared to myc-wt-XIAP (Figure 2c ; short exposure), and thus failed to show the 29 kDa cleavage product following cotreatment with TRAIL þ UVB upon proteasomal inhibition by MG132 (Figure 2c ; long exposure). Correspondingly, XIAP-D242E appeared to be more potent in inhibiting apoptosis compared with XIAP-wt (Figure 2d ).
Cleavage of XIAP is facilitated by caspase-3
Being aware of the fact that the so called specific caspase inhibitors also show non-specific side effects by inhibiting other caspases additionally (McStay et al., 2008), we took two different approaches to further characterize the caspase being responsible for endogenous XIAP cleavage and apoptosis sensitization. We first scrutinized the activation status as well as the cleavage pattern of caspase-8 being activated after TRAIL treatment, caspase-9 becoming activated upon mitochondrial outer membrane permeabilization and caspase-3 being directly inhibited by XIAP upon putative selective inhibition. In this context, caspase-3 was shown to be fully inhibited not only upon zDEVD treatment but also upon caspase-8 (zIETD) inhibition, whereas caspase-9 (zLEHD) inhibition had a minor effect on its activity as well as cleavage (Supplementary Figure S1A) . As caspase-8 activity in melanoma cells is extremely low (Supplementary Figure S1B ; see also Thayaparasingham et al., 2009) , we rather focussed on caspase-8 processing, which was slightly reduced by caspase-3 inhibition (zDEVD) but not by caspase-9 inhibition . Primary melanocytes were treated with the same low doses or with a high TRAIL (500 ng/ml) and high UVB (400 J/m 2 ) dose. After 6 h, processing of XIAP was documented by western blot analysis. (d) Cells were co-transfected with myc-wt-XIAP and the C-terminal XIAP fragment myc-D1-241-XIAP. After 24 h, transfectants pre-treated for 30 min with MG132 were stimulated with TRAIL and UVB for the indicated times. Protein status of endogenous XIAP, ectopic wt-XIAP and the D1-241-XIAP fragment was visualized by western blot analysis. In parallel, apoptosis induction was documented by poly (ADP-ribose) polymerase (PARP) cleavage.
(zLEHD; Supplementary Figure S1B ). Finally, inhibition of caspase-8 (zIETD) as well as of caspase-3 (zDEVD) was shown to fully prevent caspase-9 processing and activation (Supplementary Figure S1C) . Accordingly, caspase-9 seems to be least important in downstream caspase activation, which is in line with data shown in (a) WM-115 cells were pre-treated or not with MG132 for 30 min, followed by incubation with specific caspase inhibitors (20 mM) as indicated for another hour. After subsequent co-treatment with TRAIL (100 ng/ml) and UVB (20 J/m 2 ) for 6 h, XIAP processing was documented by western blot analysis. (b) Cells were pre-treated with the specific caspase inhibitors for 1 h and apoptosis induction was determined 16 h after TRAIL, UVB and TRAIL þ UVB stimulation in a Cell Death Detection ELISA. (c) WM-115 cells overexpressing wt-XIAP or mutated XIAP-D242E were pre-treated for 1 h with pan caspase inhibitor zVAD and/or for 30 min with proteasome inhibitor MG132 and stimulated with either TRAIL or UVB alone or combining both stimuli. After 6 h, cleavage status of endogens and ectopically expressed XIAP was determined by western blot analysis. (d) Cells overexpressing wt-XIAP or mutated XIAP-D242E were stimulated with either TRAIL or UVB or both, stimuli and apoptosis determined 16 h later in a Cell Death Detection ELISA.
XIAP cleavage by caspase-3 sensitizes melanoma to TRAIL M Hörnle et al Figure 2a . As caspase-8-induced caspase-3 activation is much stronger than vice versa (Supplementary Figure S1D) , and in view of the fact that upon caspase-3 inhibition caspase-8 is still active but XIAP cleavage is fully inhibited (see Figure 2a ), caspase-3 appears to be the most likely candidate in endogenously processing XIAP to promote its subsequent proteasomal degradation. To finally prove this issue, in a different approach we knocked down caspase-8, -9, -6 and -3, respectively, and examined the endogenous XIAP level upon apoptotic co-stimulation. In si-lacZ-treated cells, stimulation with TRAIL þ UVB caused depletion of XIAP and processing of any of the respective caspases ( Figure 3a) . However, only in cells lacking caspase-3, XIAP depletion upon TRAIL þ UVB treatment was completely abolished (Figure 3a) . To exclude a possible role of XIAP in interfering with the cross-talk between the initiator caspase-8 and -9 and the effector caspase-3, we specifically knocked down XIAP. Cells lacking XIAP showed pronounced n-fold caspase-3 activity mock xIAP-wt xIAP-D242E
Cleavage of XIAP is facilitated by caspase-3. (a) Caspase-8, caspase-9, caspase-6 and caspase-3 were knocked down, using specific small interfering RNA (siRNA). After 72 h, cells were stimulated with TRAIL (100 ng/ml) and UVB (20 J/m 2 ) for 6 h and endogenous XIAP status was documented by western blot analysis. (b) XIAP was knocked down using specific siRNA. After 72 h, WM-115 cells were pre-treated with the indicated caspase inhibitors for 1 h and stimulated with TRAIL (100 ng/ml) and UVB (20 J/m 2 ). After 6 h, caspase-3 processing was documented by western blot analysis. (c) Cells overexpressing wt-XIAP or mutated XIAP-D242E were co-stimulated with TRAIL and UVB and activities of caspase-3, -8 and -9 were determined in fluorogenic caspase activation assay using specific substrates.
XIAP cleavage by caspase-3 sensitizes melanoma to TRAIL M Hörnle et al autocatalytic processing of caspase-3 into p17 upon TRAIL þ UVB treatment (Figure 3b ). Pan caspase inhibition and only the specific blockade of caspase-8 fully abrogated caspase-3 processing, indicating caspase-8 to be the only initial activator of caspase-3. In contrast, inhibition of caspase-9 could not prevent caspase-3 processing in XIAP knockdown cells (compare Supplementary Figures S1A-D) . Only, caspase-3 inhibition could arrest caspase-3 processing at the level of p21 even in the absence of XIAP, strongly indicating that in these cell lines, final cleavage into p17 is an autocatalytic process independent of caspase-9. In the inverse approach, overexpression of the non-cleavable XIAP mutant (D242E), almost completely inhibited catalytic activity of caspase-3 (Figure 3c ). Taken together, data strongly indicated that caspase-3-mediated cleavage of XIAP is followed by autocatalytic processing into the active p17 fragment, thereby playing a major role in UVB-induced synergistic sensitization of melanoma cells to TRAIL.
Mitochondrial outer membrane permeabilization and XIAP antagonization promote its depletion by enhancing caspase-3 activation To furthermore investigate the molecular details causing synergistic induction of apoptosis, we analyzed the UVB-induced onset of cell death in TRAIL-treated cells. In co-treated cells, apoptosis was shown to be induced after 6 h as documented in a cell death detection enzyme-linked immunosorbent assay (Figure 4a ). In cells pre-treated with TRAIL alone for 16 h and subsequently exposed to sub-lethal UVB, the apoptotic response started little earlier after 4 h (Figure 4b ), nicely coinciding with the onset of XIAP depletion and full caspase-3 processing (Figure 4c ). Cytosolic Smac/ DIABLO is known to antagonize the function of XIAP and ultimately results in enhanced caspase-3 activity, which we show in turn to deplete XIAP. Therefore increased Smac release upon UVB exposure may be the underlying molecular mechanism which gives rise to accelerated XIAP depletion and enhanced susceptibility to TRAIL upon UVB exposure. Cell fractionation analysis showed a significant release of Smac as well as cytochrome c from mitochondria upon TRAIL stimulation only in conjunction with UVB exposure, being indicative for mitochondrial outer membrane permeabilization ( Figure 4d ). As cytochrome c triggers the formation of the apoptosome and caspase-9 activation, but our results so far excluded an impact of caspase-9 on XIAP cleavage, we focussed on the influence of Smac on XIAP depletion upon UVB exposure. We therefore expressed cytosolic mature Smac lacking the mitochondrial targeting sequence (MTS), which was accomplished by using the Ub fusion system previously described to bypass the mitochondrial maturation of Smac (Hunter et al., 2003) . The Ub-Smac fusion (Figure 5a ). Significantly, only overexpression of Ub-DMTS-Smac appeared to enhance XIAP depletion and caspase-3 processing (Figure 5b ), and was shown to significantly induce apoptosis in TRAIL only treated cells (Figure 5c ). This indicates that XIAP antagonizing proteins such as cytosolic Smac/DIABLO potentiate the UVB-induced XIAP depletion and TRAIL sensitization. Although cytosolic Smac efficiently initiated XIAP depletion and caspase-3 activation, small interfering RNA-mediated knockdown of endogenous Smac failed to fully prevent TRAIL þ UVB-induced apoptosis (Figure 5d ). This suggests that cytochrome c release also has an important role by inducing formation of the apoptosome and preparing the cell for caspase-9 activation. Thus, blocking mitochondrial outer membrane permeabilization by overexpression of bcl-2 almost completely inhibited apoptosis induced by the combination of TRAIL and UVB (Figure 5e ). Together, our data showed that TRAIL stimulation causes caspase-8-mediated initial caspase-3 processing generating the p21 caspase-3. Owing to strong XIAP binding, further autocatalytic activation of caspase-3 did not occur, which results in a lack of significant apoptotic outcome (Figure 6a ). Upon co-stimulation with another sub-lethal stimulus, namely UVB, the proapoptotic response of mitochondria increased, and traces of XIAP-antagonizing factors including Smac/ DIABLO released from mitochondria-not sufficient to induce apoptosis itself-initiate the distraction of XIAP from caspase-3 and its maturation into active p17. Active caspase-3 cleaves XIAP, thereby targeting it to proteasomal elimination ( Figure 6b ). To explore whether the caspase-3-dependent cleavage of XIAP may have broader therapeutic implications, we co-treated cells with TRAIL and a sub-lethal dose of the DNA damaging chemotherapeutic drug cisplatin which also preferentially induces the mitochondrial apoptotic pathway (Liu et al., 2010) . Whereas primary melanocytes remained fully resistant, WM-115 melanoma cells were shown to be resistant against 10 mM cisplatin and showed only a moderate apoptotic response to 20 mM cisplatin. Combining both concentrations of cisplatin with 100 mg/ml of TRAIL, however, caused synergistic induction of apoptosis in these cells (Figure 6c ), coinciding with XIAP depletion and full caspase-3 processing (Figure 6d ). Most importantly, application of the proteasome inhibitor MG132 also yielded the truncated 29 kDa fragment of XIAP (Figure 6d) , indicating an identical molecular mechanism to underlie the synergistic sensitization of melanoma cells to TRAIL þ cisplatin-induced apoptosis.
Discussion
Owing to the early metastatic potential, successful treatment of melanoma still represents a challenge, because the aggressive metastasis appears to be widely resistant against conventional treatment using chemotherapeutic drugs and radiotherapy. It is therefore of utmost importance to understand the molecular signaling network conveying resistance within melanoma cells in order to reveal common targets for effective therapeutic treatment. TRAIL insensitivity of melanoma has been shown to be based on the XIAP-mediated incomplete caspase-3 maturation. Combination treatment of TRAIL with UVB sensitized melanoma cells which coincided with XIAP depletion, completion of caspase-3 activation and efficient apoptotic cell death (Thayaparasingham et al., 2009 ). The common underlying mechanism included nuclear factor-kB-dependent repression of XIAP expression, resulting in depletion of this inhibitory protein over time. However, the molecular mechanism of XIAP depletion as a crucial event taking place during early onset of apoptosis remained unsolved. The present study aimed to elucidate how UVB exposure contributes to XIAP depletion and synergistically enhances TRAIL-induced apoptosis in melanoma cells.
The exact mechanisms of regulating XIAP expression in cells during apoptosis induction are controversially discussed and appear to be cell type dependent. In this context, strong evidence exists involving proteasomal degradation of XIAP (Yang et al., 2000; Dan et al., 2004; Dohi et al., 2004; Silke et al., 2004 Silke et al., , 2005 Shi et al., 2005; Hougardy et al., 2006; Sohn et al., 2006; Liou et al., 2007; Liu et al., 2007) . Besides the cellular counterpart of XIAP, mitochondrial Smac/DIABLO (Liou et al., 2007) , a number of different proteins were shown to influence proteasomal degradation of XIAP, encompassing protein kinase c (PKC) (Shi et al., 2005) , Notch (Liu et al., 2007) , Grim (Silke et al., 2004) and Akt (Dan et al., 2004) as well as IAP family members cIAP 1 þ 2 (Silke et al., 2005; Cheung et al., 2008) and survivin (Dohi et al., 2004) . Vice versa, proteasomal inhibition in certain cell types was shown to favor downregulation of XIAP, thereby triggering apoptosis (Leverkus et al., 2003; Inoue et al., 2006; Kashkar et al., 2007; Ndozangue-Touriguine et al., 2008; Blankenship et al., 2009; Hussain et al., 2009) . These contradictory data have recently been expanded by several findings displaying proteasome-independent ways of XIAP inactivation, involving a tight XIAP-caspase cross-talk beyond simple protein-protein interaction. In this context, XIAP has previously been shown to contain a caspase consensus site localized between BIR2 and BIR3, which was recognized for cleavage by different caspases in a cell-free system (Deveraux et al., 1999) . Although, caspase-mediated XIAP cleavage was documented to occur in myeloma cells upon bortezomib treatment (Desplanques et al., 2009) Upon co-irradiation with sub-lethal UVB, the intrinsic mitochondrial amplification loop becomes activated over time, causing release of Smac/DIABLO and cytochrome c. Consequently, Smac-induced distraction of XIAP from caspase-3 causes initial caspase-3 processing into catalytically active p17. Low amounts of the fully activated caspase-3 then cleave XIAP for proteasomal degradation thereby initiating a positive amplification loop causing enhanced processing of caspase-3 as well as full processing of caspase-9 within the apoptosome, thereby synergistically enhancing apoptosis. (c) Primary melanocytes as well as WM-115 melanoma cells were treated with TRAIL (100 ng/ml) or cisplatin (10 and/or 20 mM) alone or co-treated with both stimuli. After 16 h, apoptosis was determined in a Cell Death Detection ELISA. (d) Cells were pre-treated or not with the proteasome inhibitor MG132 (20 mM) for 30 min and subsequently stimulated with TRAIL or cisplatin as indicated. After 16 h, XIAP and caspase-3 processing was documented by western blot analysis. * ¼ non-specific protein band occurring upon long exposure. (Hougardy et al., 2006) and to be antagonized by the pan caspase inhibitor zVAD in keratinocytes (Leverkus et al., 2003) , the underlying molecular mechanism remained illusive. Moreover, the impact of XIAP cleavage on the apoptotic process has never been addressed before. Using specific caspase inhibitors and small interfering RNA-mediated knockdown, we clearly demonstrate that in melanoma cells, caspase-3 is responsible for endogenous XIAP cleavage as a prerequisite for proteasomal degradation and sensitization of melanoma cells to apoptosis following TRAIL treatment. Using a XIAP mutant which can not be cleaved by caspase-3, we showed for the first time that specific cleavage of XIAP is a crucial event to obtain enhanced TRAIL-induced apoptosis.
Stimulation of melanoma cells with sub-lethal UVB alone did not induce apoptosis, and neither showed caspase-3 processing nor XIAP depletion, as expected. Upon TRAIL stimulation alone, caspase-3 processing was terminated at the level of p21 because of binding by XIAP. The lack of mitochondrial outer membrane permeabilization in response to TRAIL treatment alone and the failure of cytosolic XIAP antagonizing factors resulted in constant caspase-3 inhibition by XIAP. Onset of apoptosis upon co-exposure with sub-lethal UVB coincided with mitochondrial membrane perturbation and release of cytochrome c and Smac/DIABLO. Although cytochrome c release may cause formation of the apoptosome, full caspase-9 activation is very likely inhibited due to XIAP binding as well, because XIAP was shown to bind caspase-9 with high affinity (Deveraux et al., 1999) . When, in parallel, Smac/ DIABLO is released from mitochondria, it induces distraction of XIAP from caspase-3. Liberated caspase-3 then cleaves XIAP in a positive regulatory feedback loop, thereby quickly enhancing the proteasomal XIAP turnover, amplifying its autocatalytic activation and consequently synergistically executing apoptosis via two different pathways. Despite from execution of cell death via cleavage of death substrates, activated caspase-3 may now also trigger final activation of caspase-9 by cleaving XIAP bound to caspase-9 and/or by cleavage of caspase-9 itself, thereby enhancing its catalytic activity (Twiddy and Cain, 2007) and alleviating XIAP binding (Denault et al., 2007) . Consequently, this positive amplification loop requires both cytochrome c and Smac release, although Smac appears to be the primary trigger.
Accordingly, cells ectopically expressing a cytosolic and active variant of Smac (Smac-DMTS) showed enhanced processing of caspase-3 and some XIAP depletion following stimulation with TRAIL alone. These findings are in good accordance with a recent study showing that in MCF-7 cells, TRAIL-induced apoptosis is dependent on Smac/DIABLO release from mitochondria and XIAP inhibition, rather than from cytochrome c release and caspase-9 activation (Maas et al., 2010) .
As this positive regulatory feedback loop involving caspase-mediated XIAP cleavage also appeared to synergistically sensitize melanoma cells to treatment with TRAIL and sub-lethal doses of cisplatin, it seems to have broader implications, even in a clinical perspective.
Materials and methods
Unless otherwise stated, results of Cell Death Detection enzyme-linked immunosorbent assay and caspase activation assays are presented as mean ± s.d. of three independently performed experiments. Western blot analysis and immunofluorescent images show one representative out of three independently performed experiments.
Cells and reagents
The human melanoma cell lines WM-3211 (radial growth phase), WM-115 (vertical growth phase), WM-852 (MM) were kindly provided by Dr Friedegund Meier, Department of Dermatology, University of Tu¨bingen. Cells were maintained in RPMI 1640 medium (Invitrogen, Karlsruhe, Federal Republik of Germany (FRG)) supplemented with 10% fetal calf serum (PromoCell, Heidelberg, FRG) and 1% penicillinstreptomycin (Invitrogen) at a density of 5 Â 10 5 cells/ml in a humidified atmosphere of 5% CO 2 at 37 1C. Primary melanocytes from three patients were prepared form human foreskin (Edmondson et al., 1999) , maintained in Melanocyte Growth Medium (M2, Promocell) and assayed in passage 4. UVB irradiation was performed in phosphate-buffered saline using a bank of six fluorescent bulbs (TL12, Phillips, Eindhoven, NL, USA), which emit most of the energy within the UVB range (290-320 nm), with an emission peak at 313 nm. Unless otherwise stated, cells were exposed to a sublethal UVB dose of 200 J/m 2 intending not to alter cell viability itself. Recombinant human iz-TRAIL protein, N-terminally fused to a isoleucine-zipper motif in order to constitutively build the trimerised active form (Ganten et al., 2006) was kindly provided by Dr Henning Walczak, Department of Immunology, Division of Medicine, Imperial College London. Cisplatin was administered at 10 or 20 mg/ml (Platinex; BristolMyers-Squibbs, Munich, FRG). The proteasome inhibitor MG132 (Merck, Darmstadt, FRG) was supplied at 20 mM, caspase inhibitors zVAD-fmk, zIETD-fmk, zLEHD-fmk, zDEVD-fmk and zVEID-fmk (Merck) were added at 20 mM.
Caspase activation assay
Cells were harvested and lysed in lysis buffer (20 mM Tris, pH 7.4; 200 mM NaCl; 1% Igepal and Complete protease inhibitor cocktail (Roche, Mannheim, FRG)) for 30 min on ice. After centrifugation, 15 mg cellular extract was combined with 50 ml activity buffer (220 mM manitol; 68 mM sucrose; 10 mM Hepes, pH 7.4; 5 mM Na-Pyruvat; 2 mM NaCl; 2 mM MgCl 2 ; 2.5 mM KH 2 PO 4 ; 0.5 mM ethylene glycol tetraacetic acid; 1 mM dithiothreitol (DTT), 0.1 mM phenylmethylsulfonyl fluoride and 20 mm specific caspase-3 (Ac-DEVD-AMC, Axxora, Loerrach, FRG), caspase-9 (Ac-LEHD-AMC) or caspase-8 (Ac-IETD-AMC) substrate. Respective substrate turnover was measured every 15 min over a 2 h time period in a FluoStar luminometer (BMG Lab Technologies, Offenburg, FRG) with an exitation of 390 nm and an emission of 460 nm. n-fold caspase activity was determined by calculating: emission of sample cells/emission of control cells.
Plasmids, cloning and transfection
Based on a myc-XIAP-pcDNA3 plasmid (Kashkar et al., 2007) , the non-cleavable D242E mutant form of XIAP was generated by site-directed mutagenesis using pfu-ultra poly-merase (Stratagen, La Jolla, CA, USA) followed by DpnI digestion (Fermentas Inc., Glen Burnie, MD, USA) according to the manufacturer's instructions. Deletion mutant myc-D1-241-XIAP was generated using expand high fidelity PCR system (Roche). Mitochondrial and cytosolic expression of biologically active Smac variants (Smac-wt, Smac-DMTS) were performed using Ub fusion system (Kashkar et al., 2006) , the original work was from Hunter (Hunter et al., 2003) . Bcl-2 was ectopically expressed from pcDNA3 (Kashkar et al., 2005) .
For ectopic expression, 6.5 Â 106 WM-3211 cells were electroporated with 25 mg of respective plasmids in 600 ml RPMI þ 10% fetal calf serum þ 1.25% dimethyl sulfoxide and stimulated 24 h later. Specific knockdown was facilitated by transfecting 6 Â 10 5 cells with 20 pmol of the respective small interfering RNA for caspase-8-5
0 -GCAAUCUGUCCUUCC UGAATT-3 0 , caspase-9-5 0 -GAAGAUUGUGAACAUCUUC TT-3 0 , caspase-6-5 0 -CGGCUCAUGGUACAUUCAATT-3 0 , caspase-3-5 0 -UGAUCUUACACGUGAAGAATT-3 0 , Smac/ DIABLO-5 0 -CCGCCAGGAAUCACAUUCA-3 0 , XIAP-5 0 -AUCCAUCCAUGGCAGAUUATT-3 0 or lacZ-5 0 -GCGGCU GCCGGAAUUUACCTT-3 0 for control purposes, using Lipofectamine 2000 (Invitrogen) 72 h before stimulation.
Determination of cell death
At 16 h after stimulation, cells were detached from dishes, and apoptosis was measured using a Cell Death Detection enzymelinked immunosorbent assay (Roche). The enrichment of mononucleosomes and oligonucleosomes released into the cytoplasm of cell lysates is detected by biotinylated antihistone-and peroxidase-coupled anti-DNA-antibodies and is calculated as follows: absorbance of sample cells/absorbance of control cells. The enrichment factor of 2 corresponds to 10% apoptotic cells as determined by AnnexinV staining followed by fluorescence-activated cell sorting analysis.
Western blot analysis
Cells were harvested and lysed in lysis buffer (50 mM Hepes, pH 7.5; 150 mM NaCl; 10% glycerol; 1% Triton-X-100; 1.5 mM MgCl 2 ; 1 mM ethylene glycol tetraacetic acid; 100 mM NaF; 10 mM pyrophosphate; 0.01% NaN 3 and Complete). After centrifugation, supernatants were collected and the protein content was determined by DC BioRad Protein assay kit (BioRad, Hercules, CA, USA). For mitochondrial/cytosolic fractionation, cells were lysed in cytosolic buffer (50 mM piperazine-N,N 0 -bis(2-ethansulfunic acid) (PIPES), pH 7.0; 50 mM KCl; 2 mM MgCl 2 ; 5 mM ethylene glycol tetraacetic acid; 10 mM cytochalasin B; 220 mM mannitol; 68 mM sucrose and Complete) incubated on ice for 20 min and passed 10 times through a gauge needle (26G1/2). After centrifugation at 800 r.p.m. for 10 min, cytosolic proteins and mitochondria were separated by centrifuging supernatants again at 13 000 r.p.m. for 10 min. A total of 60-80 mg of protein samples were subjected to 12-15% SDS-PAGE, blotted onto nitrocellulose membranes and incubated with antibodies directed against caspase-3, caspase-9, Smac, bcl-2 (#9662, #9502, #2954, #2872; Cell Signaling, Beverly, MA, USA), caspase-8, XIAP, poly (ADP-ribose) polymerase (#551248, #610716, #551025; BD-Biosciences, San Jose, CA, USA) and cytochrome c (BioCarta, San Diego, CA, USA; clone CTC05). Equal loading was monitored by reprobing membranes with an antibody against a-tubulin (DM1A, Neomarkers Inc., Freemount, CA, USA) or b-actin (Sigma, Munich, FRG). Horseradish peroxidase-conjugated secondary antibodies were purchased from Amersham (Buckinghamshire, UK). Bands were visualized by applying a chemiluminescense SuperSignal detection system (PIERCE, Rockford, IL, USA).
Immunofluorescence and microscopy Cells co-transfected with respective Smac-DsRed constructs, and mito-pEGFP (Clontech, Mountain View, CA, USA) were grown on coverslips, washed with phosphate-buffered saline and fixed in 4% paraformaldehyde for 15 min at room temperature. Nuclei were labeled with 4 0 ,6-diamidino-2-phenylindole (1 mg/ml), and coverslips were mounted using Fluoromount G (Southern Biotech, Birmingham, Alabama, USA). Immunofluorescence was detected by Plan-Apochromat Â 63/1.40 Oil DIC M27 objective lenses using the Apotome setting of the Zeiss Cell Observer HS system (Carl Zeiss AG, Goettingen, FRG) and the appropriate filter sets. Images were processed with Adobe photoshop.
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